Celyad Oncology SA (CLYYF)

Celyad Oncology Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 24, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	14	31	18	12	90	113
Market Cap Growth	-21.83%	71.00%	46.17%	-86.47%	-20.00%	-25.61%
Enterprise Value	14	25	13	-1	87	85
Last Close Price	0.15	0.24	0.43	0.25	4.65	9.15
PS Ratio	66.14	158.59	158.40	-	-	18459.66
PB Ratio	-3.97	57.72	2.56	2.65	1.82	2.98
P/TBV Ratio	-	60.45	2.58	2.96	10.00	-
EV/Sales Ratio	65.68	130.42	114.87	-	-	13862.06
Debt / Equity Ratio	-0.27	1.77	0.17	0.06	0.06	0.12
Net Debt / Equity Ratio	-0.01	-6.45	-0.94	-2.82	-0.63	-0.44
Net Debt / EBITDA Ratio	-0.01	0.58	0.66	0.49	1.03	0.56
Net Debt / FCF Ratio	-0.01	0.58	0.37	0.43	1.01	0.49
Asset Turnover	0.02	0.01	0.01	-	-	0
Quick Ratio	0.42	1.79	3.34	1.31	2.34	1.53
Current Ratio	0.66	2.29	3.79	1.42	2.48	1.67
Return on Equity (ROE)	-7871.95%	-170.92%	-159.08%	-170.72%	-71.05%	-44.91%
Return on Assets (ROA)	-43.41%	-27.99%	-33.14%	-31.92%	-23.32%	-21.04%
Return on Capital Employed (ROCE)	-325.40%	-82.90%	-71.50%	-273.90%	-41.20%	-48.40%
Earnings Yield	-52.47%	-19.74%	-52.29%	-358.06%	-33.38%	-18.64%
FCF Yield	-	-19.26%	-99.65%	-246.08%	-33.97%	-30.14%
Buyback Yield / Dilution	-17.90%	-61.06%	-13.84%	-44.80%	-11.92%	-11.33%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.